FDA Approves Evenity

April 9, 2019 — The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are…

FDA Approves Ketamine-Like Drug for Severe Depression

WEDNESDAY, March 6, 2019 — The U.S. Food and Drug Administration on Tuesday approved the nasal spray medication esketamine — a relative of the club drug and anesthetic ketamine — for use against severe depression. Sold as Spravato, the fast-acting drug becomes the first new type of medicine approved in…

FDA Approves Cablivi for Rare Blood-Clotting Disorder

WEDNESDAY, Feb. 6, 2019 — Cablivi (caplacizumab-yhdp) injection has been approved by the U.S. Food and Drug Administration to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP). “Patients with aTTP endure hours of treatment with daily plasma exchange, which requires being attached to a machine that takes blood out of…